SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Damora Therapeutics Presents DMR-001 Development Plan

The company targets clinical proof-of-concept readouts from mid-2027.

DMRA

Related stories